Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

Blood

Volumn 104, Issue 2, 2004, Pages 307-313

  Tartaglia, Marco ^a   Martinelli, Simone ^b   Cazzaniga, Giovanni ^b   Cordeddu, Viviana ^b   Iavarone, Ivano ^b   Spinelli, Monica ^b   Palmi, Chiara ^b   Carta, Claudio ^b   Pession, Andrea ^b   Aricò, Maurizio ^b   Masera, Giuseppe ^b   Basso, Giuseppe ^b   Sorcini, Mariella ^b   Gelb, Bruce D ^b   Biondi, Andrea ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CY IMMUNOGLOBULIN M; CYTOKINE RECEPTOR; GROWTH FACTOR; IMMUNOGLOBULIN M; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CHILD; CHILDHOOD LEUKEMIA; FEMALE; GENE; GENE MUTATION; GERM LINE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; NOONAN SYNDROME; ONCOGENE K RAS; ONCOGENE K RAS 2; ONCOGENE N RAS; PRIORITY JOURNAL; PTPN11 GENE; SIGNAL TRANSDUCTION; T LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA; TEL AML1 GENE;

EID: 3142620903     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3876     Document Type: Article

References (45)

1. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284-293.
2. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol. 2004;11:44-50.
3. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong A, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase. Mol Cell Biol. 2000;20:8513-8525.
4. Shi Z-Q, Yu D-H, Park M, Marshall M, Feng G-S. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol. 2000;20:1526-1536.
5. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP-2 in epidermal growth factor receptor signaling. Mol Cell Biol. 2003;23:7875-7886.
6. Yu WM, Hawley TS, Hawley RG, Qu CK. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene. 2003;22:5995-6004.
7. Tang TL, Freeman RM Jr, O'Reilly AM, Neel BG, Sokol SY. The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell. 1995;80:473-483.
8. Saxton TM, Henkemeyer M, Gasca S, et al. Abnormal mesoderm pattering in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 1997;16:2352-2364.
9. Qu C-K, Yu W-M, Azzarelli B, Cooper S, Broxmeyer HE, Feng G-S. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol. 1998;18:6075-6082.
10. Saxton TM, Ciruna BG, Holmyard D, et al. The SH2 tyrosine phosphatase Shp2 is required for mammalian limb development. Nat Genet. 2000;24:420-423.
11. Chen B, Bronson RT, Klaman LD, et al. Mice mutants for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet. 2000;24:296-299.
12. Qu CK, Shi ZQ, Shen R, Tsai FY, Orkin SH, Feng GS. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol. 1997;17:5499-5507.
13. Qu C-K, Nguyen S, Chen J, Feng G-S. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood. 2001;97:911-914.
14. Chan RJ, Johnson SA, Li Y, Yoder MC, Feng GS. A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis. Blood. 2003;102:2074-2080.
15. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-468.
16. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555-1563.
17. Tartaglia M, Gelb BD. PTPN11 and the Noonan syndrome. In: Epstein CJ, Erickson RP, Wynshaw-Boris A, eds. Inborn Errors of Development. The Molecular Basis of Clinical Disorders of Morphogenesis. San Francisco, CA: Oxford University Press; 2004:895-903.
18. Bader-Meunier B, Tchernia G, Miélot F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr. 1997;130:885-889.
19. Fukuda M, Horibe K, Miyajima Y, Matsumoto K, Nagashima M. Spontaneous remission of JCML in an infant with NS. J Pediatr Hematol Oncol. 1997;19:177-178.
20. Choong K, Freedman MH, Chitayat D, Kelly EN, Taylor G, Zipursky A. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol. 1999;21:523-527.
21. Piombo M, Rosanda C, Pasino M, Marasini M, Cerruti P, Comelli A. Acute lymphoblastic leukemia in Noonan syndrome: report of two cases. Med Pediatr Oncol. 1993;21:454-455.
22. Attard-Montalto SP, Kingston JE, Eden T. Noonan's syndrome and acute lymphoblastic leukaemia. Med Pediatr Oncol. 1994;23:391-392.
23. Johannes JM, Garcia ER, De Vaan GA, Weening RS. Noonan's syndrome in association with acute leukemia. Pediatr Hematol Oncol. 1995;12:571-575.
24. Tartagiia M, Niemeyer CM, Fragale A, et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148-150.
25. Loh ML, Vattikuti S, Schubbert S, et al. Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis. Blood. Prepublished on November 26, 2003, as DOI 10.1182/blood-2003-09-3287. (Now available as Blood. 2004;103:2325-2331.)
26. Loh ML, Vattikuti S, Schubbert S, et al. Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis. Blood. Prepublished on November 26, 2003, as DOI 10.1182/blood-2003-09-3287. (Now available as Blood. 2004;103:2325-2331.)
27. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. 1995;9:1783-1786.
28. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
29. Hiddemann W, Schumann J, Andreef M, et al. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet. 1984;13:181-183.
30. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441-450.
31. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
32. Pazdrak K, Adachi T, Alam R. Src homology 2 protein tyrosine phosphatase (SH PTP2)/Src homology 2 phosphatase 2 (SHP2) tyrosine phosphatase is a positive regulator of the interleukin 5 receptor signal transduction pathways leading to the prolongation of eosinophil survival. J Exp Med. 1997;186:561-568.
33. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000;275:27845-27850.
34. Yu WM, Hawley TS, Hawley RG, Qu CK. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene. 2003;22:5995-6004.
35. Yokota S, Nakao M, Horiike S, et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol. 1998;67:379-387.
36. Lübbert M, Mirro J Jr, Miller CW, et al. N-Ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood. 1990;75:1163-1169.
37. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood. 1990;75:1684-1690.
38. Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP-2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mut. 2004;23:267-277.
39. Digilio MC, Conti E, Sarkozy A, et al. Grouping of multiple-lentigines/ LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet. 2002;71:389-394.
40. ras. Blood. 1994;84:3435-3439.
41. de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 1998;10:619-628.
42. Miyajima A, Ito Y, Kinoshita T. Cytokine signaling for proliferation, survival, and death in hematopoietic cells. Int J Hematol. 1999;69:137-146.
43. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17:1263-1293.
44. Byrne JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br J Haematol. 1998;100:256-264.
45. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179-198.